探讨血小板膜糖蛋白在免疫性血小板输注无效中的临床意义

宋 晨辉, 梁 静
新疆医科大学第六附属医院 830000

摘要

目的：探究血小板膜糖蛋白在免疫性血小板输注无效发生机制中的重要作用。方法：采用流式细胞技术检测免疫性PTR患者和输注血小板有效者血小板膜糖蛋白。采用SPSS23.0统计学软件对所得数据进行分析。结果：PTR患者CD36、CD61表达较血小板输注有效组显著降低，而两组样本中CD41a表达情况无显著差异。结论：免疫性PTR的发生不能完全归于血小板抗体的产生，患者血小板膜糖蛋白的异常表达提示血小板膜糖蛋白可能参与免疫性PTR的发生。

关键词

免疫性血小板输注无效；血小板膜糖蛋白；血小板特异性抗体

参考

[1]Hod E,Schwartz J.Platelet transfusion refractoriness.[J].British Journal of Haematology,2010,142(3):348-360.[2]杨小莉,余泽波.血小板输注无效原因及对策研究进展[J].检验医学与临床,2019,16(07):127-130.[3]周燕,李丽兰,钟周琳,等.造血干细胞移植术后抗-CD36注无效症和相关病例的实验研究[J].中国实验血液学杂志,2018,26(2):541-546.[4]Weinstock C,Schnaidt M.Human Leucocyte Antigen Sensitisation and Its Impact on Transfusion Practice[J].Transfusion Medicine and Hemotherapy,2019,46(5).[5]Doughty H A,Murphy M F,Metcalfe P,et al.Relative Importance of Immune and Non-Immune Causes of Platelet Refractoriness[J].Vox Sanguinis,1994.[6]刘瑛，许先国，马开荣，等．HLAⅠ基因型配合输注策略用于免疫性血小板输注无效的实验研究．中国输血杂志，2021,34(8)：832-835.[7]Silberstein,Leslie,E,et al.Platelet refractoriness:it's not the B-all and end-all[J].Blood:The Journal of the American Society of Hematology,2016,127:1740-1741.[8]Vassallo R R,Norris P J.Can we“terminate”alloimmune platelet transfusion refractoriness?[J].Transfusion,2016,56(1):19-22.[9]Zhao BW,XH Zhang,Gu Y,et al.Anti-platelet aggregation mechanism of Xixian Tongshuan Preparation based on molecular simulation methods[J].China journal of Chinese materia medica,2019, 44(9): 1882-1888[10]Dan X U,Cheng-Fu J I,Chen C,et al.The Effect of Dexamethasone Combinated with Caffeic Acid Tablet on PAIgG and GP Ⅱ b/Ⅲ a Levels in Patients with Primary Immune Thrombocytopenia[J].Journal of Clinical Transfusion and Laboratory Medicine,2019,9(11):103-106[11]Malakootikhah,Naghavi H,Firouzabadi N,et al.Association of human platelet alloantigens encoding gene polymorphisms with the risk of Coronary artery disease in Iranian patients[J].BMC Cardiovascular Disorders,2021,21(1):3-9[12]Srzentic S J,Lilic M,Vavic N,et al.Genotyping of Eight Human Platelet Antigen Systems in Serbian Blood Donors:Foundation for Platelet Apheresis Registry[J].Transfusion Medicine and Hemotherapy, 2021,10(11):1-6[13]Qiao,Deng S,Zhang M, et al.Effects of two different glycoprotein platelet Ⅱb/Ⅲa inhibitors and the clinical endpoints in patients with intracranial Pipeline flow diverter implant[J].Journal of Interventional Medicine, 2020,3(4):19-24[14] 刘双.血小板生成素受体激动剂对慢性ITP FcγRs 的调控研究.山东大学,2017.